CRISPR/Cas9 在癌症治疗中的应用：临床转化、机制策略与治疗方向

CRISPR/Cas9 in cancer therapy: clinical translation, mechanistic strategies, and therapeutic directions.

序贯 CD2/CD3/CD28 激活改善 T 细胞受体 α 恒定区的非病毒大载荷嵌合抗原受体敲入

Sequential CD2/CD3/CD28 activation improves nonviral large-payload chimeric antigen receptor knock-in at the T cell receptor α constant locus.

FATP2 介导的脂质代谢增强 B 细胞急性淋巴细胞白血病中 CAR-T 细胞治疗的耐药

FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia.

整合素α4 抑制可延长移植 CD19 阴性 CAR-T19 后复发 B-ALL 的 NSG 小鼠的生存期

Integrin Alpha 4 Inhibition Prolongs the Survival of NSG Mice Engrafted with CD19-Negative Post-CART19 Relapsed B-ALL.

非基因编辑、靶向 CD19 的同种异体 CAR-T 细胞疗法治疗复发/难治性 B 细胞急性淋巴细胞白血病：一项开放标签、单臂 1 期研究

Non-gene-edited, CD19-targeted, allogeneic CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia: an open-label, single-ar

TP53 缺失诱导与 B-ALL 中 CAR-T 细胞耗竭加速相关的低黏附转录组特征

TP53 deficiency induces a low-adhesion transcriptomic signature correlating with accelerated CAR-T cell exhaustion in B-ALL.

我们的体外研究结果表明，B-ALL 细胞中 TP53 缺失会下调黏附网络并损害免疫原性信号，这与 CAR-T 细胞耗竭加速相关。

CAR-T 细胞治疗在肿瘤免疫治疗中的应用——生物学、临床成功与新兴挑战：综述

CAR-T cell therapy in cancer immunotherapy - Biology, clinical successes, and emerging challenges: A review.

CAR 疗法在肿瘤与自身免疫领域的演进：机制见解与治疗创新

The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations.

CRISPR 基因组编辑与白血病免疫治疗的未来

CRISPR Genome Editing and the Future of Leukaemia Immunotherapy.

虽然碱基编辑在精确性和功能保留方面表现优异，但当需要完全基因敲除时，CRISPR-Cas9 仍是首选。

利用 CD2 轴拓宽并增强 CAR-T 细胞疗法的疗效

Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.